<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962452</url>
  </required_header>
  <id_info>
    <org_study_id>MiDiSeq</org_study_id>
    <nct_id>NCT03962452</nct_id>
  </id_info>
  <brief_title>Mitochondrial Diseases - Long-read Genome and Transcriptome Sequencing in Cases Unresolved After Short-read Genomics</brief_title>
  <official_title>Mitochondrial Diseases - Long-read Genome and Transcriptome Sequencing in Cases Unresolved After Short-read Genomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MiDiSeq project will enroll 20 unresolved index patients with suspected mitochondrial
      disease prioritized for genomic analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the MiDiSeq (monocentric, prospective, open-label diagnostic) project, patients with
      suspected mitochondrial disease prioritized for i) high a priori probability for a genetic
      basis (e.g. positive family history) as well as availability of (ii) fibroblast cell lines
      with a biochemically defined phenotype, (iii) parental samples, (iv) short read whole genome
      and transcriptome datasets and (v) optional additional metabolomics and proteomics data.

      The following questions will be leading the project:

      i) to systematically benchmark different sequencing technologies to detect genetic and
      epigenetic variation and their impact on gene regulation.

      (ii) to further develop algorithms for integrative analyses of different 'omics datasets.

      (iii) to expand the analysis from coding Single-Nucleotide Variants (SNVs) and regulatory
      mutations to structural variants (SVs), repeat expansions and contractions, low complexity
      regions and epigenetic signatures.

      (iv) to identify novel alterations and disease mechanisms. (v) to gain fundamental new
      insights into disease mechanisms and cellular biology.

      (vi) to improve genetic diagnostics of future rare disease patients and to evaluate
      personalized therapeutic options.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Epi)Genetic variation</measure>
    <time_frame>1 Day</time_frame>
    <description>Number of (Epi)Genetic variation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rare Diseases</condition>
  <condition>Genetic Predisposition</condition>
  <arm_group>
    <arm_group_label>Mitochondrial disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Unresolved index patients with suspected mitochondrial disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Next Generation Sequencing (NGS)</intervention_name>
    <description>Determining the nucleic acid sequence</description>
    <arm_group_label>Mitochondrial disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Unclear diagnosis Suspected genetic cause of the disease

        Exclusion Criteria:

        Missing informed consent of the patient/ legal guardian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Haack, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Haack, Dr.</last_name>
    <phone>+49 7071 298</phone>
    <phone_ext>77696</phone_ext>
    <email>tobias.haack@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olaf Rieß, Prof. Dr.</last_name>
    <phone>+49 7071 298</phone>
    <email>olaf.riess@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rare Diseases</keyword>
  <keyword>Genetic Predisposition</keyword>
  <keyword>Epigenetic variation</keyword>
  <keyword>Omics</keyword>
  <keyword>Genetic variation</keyword>
  <keyword>Mitochondrial disease</keyword>
  <keyword>Next Generation Sequencing (NGS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

